HCA

HCA Healthcare, Inc.

$423.11 +6.04 (+1.45%) At close · Jul 7

Market Cap

$93.86B

221,839,800

Equibles Rating blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 16.9 · calm Equity put/call 0.86

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −8%

below

Price vs 50-day avg +5%

above

RSI (14) 67

neutral

MACD trend Positive

52-week position 42%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +14%

trailing

6-month return −11%

trailing

YTD return −9%

this year

Relative strength −18%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $402 › 200d $460 — 200d above 50d

Institutional flow Distributing

49 of 1,421 funds reported for Jun 30 · net -58.2K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

2.35% of float · ▲ +0.0% MoM · 2.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

1,421 holders — near 3-yr high, broad support

Squeeze score 48

elevated · 0–100

Fundamentals

Strong

Revenue growth +7%

Y/Y

EPS growth +29%

Y/Y

Free cash flow $7.7B

Valuation P/E 14.6

below peers

Buyback $1.6B

remaining

Balance sheet $48.1B

net debt

Quant / Vol

risk profile

Moderate

Volatility 27%

annualized · 1-yr

Max drawdown −34%

past year

ATR 2.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

Next earnings call

Jul 24, 2026 Est · unconfirmed · in 2 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Apr 29, 2026

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−8% Bearish

Price vs 50-day avg

+5% Bullish

RSI (14)

67 Neutral

MACD trend

Positive Bullish

52-week position

42% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $402 › 200d $460 — 200d above 50d

Institutional flow Distributing

49 of 1,421 funds reported for Jun 30 · net -58.2K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

2.35% of float · ▲ +0.0% MoM · 2.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

1,421 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $328 Now $423 · 42% 52-wk high $556

vs 200-day avg -8% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	3.8B	first quarter of 2026	—

Ambulatory sites of care	2,600	As of March 31, 2026	—
Hospitals	189	As of March 31, 2026	—
Same facility admissions	0.9%	first quarter of 2026	—

Same facility emergency room visits	0.3%	first quarter of 2026	—

Same facility equivalent admissions	1.3%	first quarter of 2026	—

Same facility inpatient surgeries	-0.3%	first quarter of 2026	—
Same facility outpatient surgeries	-1.7%	first quarter of 2026	—
Same facility revenue per equivalent admission	3.1%	first quarter of 2026	—

adjusted EBITDA margin change vs prior year non-GAAP	-50	Q1 call	—
commercial equivalent admissions growth excluding exchanges vs prior year	0.6%	Q1 call	—
emergency room capacity increase vs prior year	4%	Q1 call	—
estimated adjusted EBITDA impact from exchanges vs prior year non-GAAP	$150M	Q1 call	—
estimated adverse adjusted EBITDA impact from respiratory season and winter storm non-GAAP	$180M	Q1 call	—
hospital beds increase through capital spending vs prior year	1%	Q1 call	—
Medicaid equivalent admissions growth vs prior year	0.3%	Q1 call	—
Medicaid supplemental payment net benefit increase vs prior quarter non-GAAP	$200M	Q1 call	—
Medicare equivalent admissions growth vs prior year	1.9%	Q1 call	—
respiratory-related admissions change vs prior year	-42%	Q1 call	—
respiratory-related emergency room visits change vs prior year	-32%	Q1 call	—
same-facility admissions growth vs prior year	0.9%	Q1 call	—
same-facility equivalent admissions growth vs prior year	1.3%	Q1 call	—
same-facility ER visits growth vs prior year	0.3%	Q1 call	—
same-facility exchange equivalent adjusted admissions change vs prior year non-GAAP	-15%	Q1 call	—
same-facility inpatient surgeries change vs prior year	-0.3%	Q1 call	—
same-facility outpatient surgeries change vs prior year	-1.7%	Q1 call	—
same-facility uninsured equivalent admissions change vs prior year	16%	Q1 call	—
sites of care expansion vs prior year	4%	Q1 call	—
Diluted earnings per share, as adjusted non-GAAP	$8.01	Q4 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Medical Care Facilities — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
HCA HCA Healthcare, Inc. this stock	$93.86B	-9.2%	+7.1%	14.6	2.4%
FSNUY Fresenius SE & Co. KGaA	$28.09B	-13.0%	—	—	0.0%
THC Tenet Healthcare Corp	$17.76B	+5.1%	-2.3%	10.7	4.7%
DVA Davita Inc.	$15.04B	+106.2%	+6.5%	21.9	7.2%
FMS Fresenius Medical Care AG	$13.00B	+1.6%	—	—	0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

1,417

% held: 58.8%
Reported: 49 of 1,421
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

876

View

Short & Settlement

Short Interest Rising

Shares short

5.2M

Days to cover: 2.7d
Change: +27 sh

View

Short Volume

Short vol %

73%

As of: Jul 8, 2026

Short Total

View

Fails to Deliver

FTD shares

2.3K

Value: $874.1K
As of: Jun 8, 2026

View

Off-Exchange

Off-exchange %

39.7%

Week of: Jun 15, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Lisa McClain

Amount: $1.0K–$15.0K
Traded: Sep 11, 2025

View

Financials

Revenue (FY)

$75.6B

Net income (FY): $6.8B
EPS diluted: $28.33

View

Buybacks

Authorized

$10.0B

Remaining: $1.6B

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 18, 2026
This year: 10

View

Proposed Sales

Value

$903.5K

Shares: 1.7K
Filed: Feb 18, 2026

View

Earnings & Events

Earnings Calls

Last call

Apr 24, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
HCA	+7.9%	+13.7%	-10.7%	+8.5%	-9.2%
SPY	+0.9%	+1.4%	+7.6%	+0.1%	+9.7%
vs SPY	+6.9%	+12.3%	-18.2%	+8.4%	-18.9%

Capital returns

Latest dividend

$0.78 / share · ex Jun 16, 2026

Raised 8.3%

Paid (TTM)

$3.00 / share · 4 payouts

Dividend yield (TTM, derived)

0.71%

Buyback program · as of Dec 31, 2022

Authorized

$10.00B

Spent (derived)

$8.41B

Remaining

$1.59B

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 860730 CUSIP 40412C101 13F (30d) 78 filings 52 filers Visit website Investor relations

HCA

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns